3-(6-benzhydryl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-3-yl)-1-(1H-benzimidazol-2-yl)propan-1-one | 1440546-57-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(6-benzhydryl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-3-yl)-1-(1H-benzimidazol-2-yl)propan-1-one
• CAS: 1440546-57-5
• 化学式: C₂₆H₂₀N₆OS
• 分子量: 464.55
• InChiKey: SNXAQPBSZFOBBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  117
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  邻苯二胺 在 盐酸 、 硫酸 、 一水合肼 、 potassium hydroxide 、 三氯氧磷 作用下， 以 甲醇 、 乙醇 、 水 、 正丁醇 为溶剂， 反应 35.0h， 生成 3-(6-benzhydryl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-3-yl)-1-(1H-benzimidazol-2-yl)propan-1-one
  参考文献：
  名称：

  Benzimidazole clubbed with triazolo-thiadiazoles and triazolo-thiadiazines: New anticancer agents

  摘要：

  Two series of Benzimidazole clubbed with triazolo-thiadiazoles (5a-q, 5r, 5s and 5x-a(1)) and triazolo-thiadiazines (5t-w) were synthesized with an aim to produce promising anticancer agents. In vitro anticancer activities of synthesized compounds were investigated at the National Cancer Institute (NCI) against NCI 60 cell line panel; results showed good to remarkable broad-spectrum anticancer activity. Among them, the compound 5h (NCS: 760452, 1-(1H-benzo [d] imidazol-2-yl)-3-(6-(2,4-dichlorophenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-3-yl) propan-l-one) exhibited significant growth inhibition with GI(50) values ranging from 0.20 to 2.58 mu M and found superior selectivity for the leukemia cell lines and further screened at 10-fold dilutions of five different concentrations (0.01, 0.1, 1, 10 and 100 mu M). The 5h may possibly be used as lead compound for developing new anticancer agents. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.07.011

文献信息

• Benzimidazole clubbed with triazolo-thiadiazoles and triazolo-thiadiazines: New anticancer agents
  作者：Asif Husain、Mohd Rashid、M. Shaharyar、Anees A. Siddiqui、Ravinesh Mishra

  DOI：10.1016/j.ejmech.2012.07.011

  日期：2013.4

  Two series of Benzimidazole clubbed with triazolo-thiadiazoles (5a-q, 5r, 5s and 5x-a(1)) and triazolo-thiadiazines (5t-w) were synthesized with an aim to produce promising anticancer agents. In vitro anticancer activities of synthesized compounds were investigated at the National Cancer Institute (NCI) against NCI 60 cell line panel; results showed good to remarkable broad-spectrum anticancer activity. Among them, the compound 5h (NCS: 760452, 1-(1H-benzo [d] imidazol-2-yl)-3-(6-(2,4-dichlorophenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-3-yl) propan-l-one) exhibited significant growth inhibition with GI(50) values ranging from 0.20 to 2.58 mu M and found superior selectivity for the leukemia cell lines and further screened at 10-fold dilutions of five different concentrations (0.01, 0.1, 1, 10 and 100 mu M). The 5h may possibly be used as lead compound for developing new anticancer agents. (C) 2012 Elsevier Masson SAS. All rights reserved.